QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Soligenix, Inc. (SNGX) Receives Orphan Drug Designation For OrbeShield™ 0 comments
    Jan 2, 2013 5:48 PM | about stocks: SNGX

    The U.S. FDA's Office of Orphan Products Development has granted orphan drug designation to Soligenix Inc.'s OrbeShield™ (oral BDP) as a measure to prevent death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

    Oral BDP, a highly potent, topically active corticosteroid, is the active ingredient in OrbeShield™, which is currently being developed for the treatment of gastrointestinal acute radiation syndrome (GI ARS), a leading cause of mortality following high doses of total body irradiation (NYSE:TBI).

    Orphan drug designation provides a seven-year term of market exclusivity for oral BDP upon final FDA approval, and positions Soligenix to leverage a wide range of financial and regulatory benefits, such as government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application for oral BDP, and certain tax credits.

    "The FDA's decision to grant oral BDP orphan drug designation signifies an important step for Soligenix as we continue to expand our oral BDP pipeline," Christopher J. Schaber , PhD, president and CEO of Soligenix. "The marketing exclusivity that orphan drug designation imparts adds significantly to the existing patent estate surrounding OrbeShield™. We believe that OrbeShield™ has the potential to be a significant advancement in the preparation necessary for this nation to manage a public health emergency like a nuclear attack."

    For more information visit soligenix.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: SNGX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.